Advanced Therapeutics Sustainability Due Diligence & Market Research

Advanced Therapeutics Market Overview

Advanced therapeutics are the biologic and genetic medicines reshaping treatment in cancer, rare disease and immunology. The sector covers antibody medicines, including monoclonal antibodies, bispecific antibody formats, antibody-drug conjugates and biosimilars, cell therapies, including CAR-T cell platforms and allogeneic cell therapy products, genetic medicines, including gene therapy vectors, CRISPR-based gene editing and RNA-based therapeutics, and the cell therapy kits used to manufacture them.

Demand rests on approvals that widen indications and move treatment into earlier lines, on growing evidence of durable benefit, and on manufacturing advances that lower the cost of each dose or patient. Reimbursement and access policy decide much of the pace. Health technology assessment, price negotiation, tenders and biosimilar substitution shape how quickly new medicines reach patients, while accredited treatment centers, contract manufacturing capacity and regulatory pathways for advanced therapies set how far they can scale.

ANMD studies in this sector size each therapeutic market from 2020 to 2032 by value and by patients treated, doses or batches, and break it down by modality, product type, indication, care setting and buyer across seven regions, with country modules for the leading markets. Each study pairs the market analysis with sustainability due diligence covering patient access and affordability, manufacturing energy, water and waste, supply-chain resilience, and the evidence behind clinical and access claims.

Key findings across our studies

• Eight of the ten markets at least double in value between 2025 and 2032. CRISPR-based gene editing grows fastest from a small base, and bispecific antibodies, CAR-T platforms, cell therapy kits and allogeneic products follow, while monoclonal antibodies grow steadily on a very large base and RNA therapeutics grow more slowly as pandemic vaccine demand gives way to durable therapy.
• Next-generation designs take share within each class. Engineered antibodies gain on conventional formats, allogeneic, iPSC-derived and in-vivo platforms gain on autologous CAR-T, in-vivo delivery takes a large share of gene editing, self-amplifying RNA is the fastest-growing RNA modality and non-viral vectors are the fastest-growing vector type.
• Treatment is moving earlier and beyond late-line cancer. CAR-T and bispecifics move into earlier lines, solid tumors, autoimmune disease and outpatient care, antibody-drug conjugates widen into new indications, and allogeneic therapies extend into immunology.
• Patient numbers grow faster than value in several markets as prices ease. Biosimilar treated doses, CAR-T patients and cell therapy kit units all rise faster than market value, widening access as competition, scale and process improvements lower the price per patient or dose.
• Manufacturing is industrializing. Closed and automated formats become the majority of cell therapy kit value, contract manufacturing carries more than half of gene therapy vector value, and process intensification lowers the cost of each delivered dose.
• North America is the largest region in nine of the ten markets, and Europe leads biosimilars. Asia Pacific grows faster than both North America and Europe in all ten markets, led by the clinical pipeline and manufacturing capacity in China and by cost-innovative therapies in India.

Studies in this sector

• Allogeneic Cell Therapy Products
• Antibody-Drug Conjugates (ADCs)
• Biosimilar Drug Formulations
• Bispecific Antibody Formats
• CAR-T Cell Platforms
• Cell Therapy Kits
• CRISPR-Based Gene Editing Therapeutics
• Gene Therapy Vectors
• Monoclonal Antibody Products
• RNA-Based Therapeutics

Frequently Asked Questions